Update and critical appraisal of the use of topical azithromycin ophthalmic 1% (AzaSite®) solution in the treatment of ocular infections

Update and critical appraisal of the use of topical azithromycin ophthalmic 1% (AzaSite®) solution in the treatment of ocular infections

Canan Asli UtineYeditepe University, Department of Ophthalmology, Istanbul, Turkey and Ocular Surface Disease and Dry Eye Clinic, Cornea and External Disease Service, The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USAAbstract: Azithromycin is an azalide tha...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Utine CA
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2011
Materias:
Ophthalmology
RE1-994
Acceso en línea:https://doaj.org/article/a993340aa4c94f4084a85d2aeaaa5a9c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:a993340aa4c94f4084a85d2aeaaa5a9c
record_format dspace
spelling oai:doaj.org-article:a993340aa4c94f4084a85d2aeaaa5a9c2021-12-02T05:06:53ZUpdate and critical appraisal of the use of topical azithromycin ophthalmic 1% (AzaSite®) solution in the treatment of ocular infections1177-54671177-5483https://doaj.org/article/a993340aa4c94f4084a85d2aeaaa5a9c2011-06-01T00:00:00Zhttp://www.dovepress.com/update-and-critical-appraisal-of-the-use-of-topical-azithromycin-ophth-a7652https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Canan Asli UtineYeditepe University, Department of Ophthalmology, Istanbul, Turkey and Ocular Surface Disease and Dry Eye Clinic, Cornea and External Disease Service, The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USAAbstract: Azithromycin is an azalide that acts by binding to the 50S ribosomal subunit of susceptible microorganisms and interfering with microbial protein synthesis. Azithromycin is also noted by anti-inflammatory and immunomodulatory activity. AzaSite® (Inspire Pharmaceuticals, Inc, Durham, NC) is azithromycin ophthalmic solution, 1% formulated in polycarbophil (the aqueous mucoadhesive polymer contained in DuraSite®) that delivers high and prolonged azithromycin concentrations in a variety of ocular tissues, including the conjunctiva, cornea and particularly the eyelid. AzaSite was approved by the Food and Drug Administration (FDA) in the US in 2007, for the treatment of bacterial conjunctivitis caused by susceptible isolates. This article aims to evaluate the peer-reviewed published scientific literature and to define well-established uses of AzaSite eye drops in the field of ocular infections.Keywords: azithromycin, AzaSite, DuraSiteUtine CADove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2011, Iss default, Pp 801-809 (2011)
institution DOAJ
collection DOAJ
language EN
topic Ophthalmology
RE1-994
spellingShingle Ophthalmology
RE1-994
Utine CA
Update and critical appraisal of the use of topical azithromycin ophthalmic 1% (AzaSite®) solution in the treatment of ocular infections
description Canan Asli UtineYeditepe University, Department of Ophthalmology, Istanbul, Turkey and Ocular Surface Disease and Dry Eye Clinic, Cornea and External Disease Service, The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USAAbstract: Azithromycin is an azalide that acts by binding to the 50S ribosomal subunit of susceptible microorganisms and interfering with microbial protein synthesis. Azithromycin is also noted by anti-inflammatory and immunomodulatory activity. AzaSite® (Inspire Pharmaceuticals, Inc, Durham, NC) is azithromycin ophthalmic solution, 1% formulated in polycarbophil (the aqueous mucoadhesive polymer contained in DuraSite®) that delivers high and prolonged azithromycin concentrations in a variety of ocular tissues, including the conjunctiva, cornea and particularly the eyelid. AzaSite was approved by the Food and Drug Administration (FDA) in the US in 2007, for the treatment of bacterial conjunctivitis caused by susceptible isolates. This article aims to evaluate the peer-reviewed published scientific literature and to define well-established uses of AzaSite eye drops in the field of ocular infections.Keywords: azithromycin, AzaSite, DuraSite
format article
author Utine CA
author_facet Utine CA
author_sort Utine CA
title Update and critical appraisal of the use of topical azithromycin ophthalmic 1% (AzaSite®) solution in the treatment of ocular infections
title_short Update and critical appraisal of the use of topical azithromycin ophthalmic 1% (AzaSite®) solution in the treatment of ocular infections
title_full Update and critical appraisal of the use of topical azithromycin ophthalmic 1% (AzaSite®) solution in the treatment of ocular infections
title_fullStr Update and critical appraisal of the use of topical azithromycin ophthalmic 1% (AzaSite®) solution in the treatment of ocular infections
title_full_unstemmed Update and critical appraisal of the use of topical azithromycin ophthalmic 1% (AzaSite®) solution in the treatment of ocular infections
title_sort update and critical appraisal of the use of topical azithromycin ophthalmic 1% (azasite®) solution in the treatment of ocular infections
publisher Dove Medical Press
publishDate 2011
url https://doaj.org/article/a993340aa4c94f4084a85d2aeaaa5a9c
work_keys_str_mv AT utineca updateandcriticalappraisaloftheuseoftopicalazithromycinophthalmic1azasiteampregsolutioninthetreatmentofocularinfections
_version_ 1718400613413289984

Ejemplares similares